EUVIMEDEUVIMED entdecken
Open Access

Keratin gene expression signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma

Aohui Chen, Ting Gao, Fengqi Liu, Mingyue Zhao, Ruizhen Bai, Quan Liu

Oncology Letters · 21.07.2026 · 32 (3) · 1-13

DOI: 10.3892/ol.2026.15774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 21.07.2026. Verfasst von Aohui Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi Medical College, Jiangnan University, Wuxi, Jiangsu 214122, P.R. China. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

immunotherapykeratin geneslung adenocarcinomamachine learningprognostic signature

Autor:innen und Institutionen

  • Wuxi Medical College, Jiangnan University, Wuxi, Jiangsu 214122, P.R. China.
  • Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214122, P.R. China.
  • Department of Medical Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214122, P.R. China.

Zitieren

APA

Chen, A., Gao, T., Liu, F., Zhao, M., Bai, R., & Liu, Q. (2026). Keratin gene expression signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma. Oncology Letters, 32(3), 1-13. https://doi.org/10.3892/ol.2026.15774

Vancouver

Chen A, Gao T, Liu F, Zhao M, Bai R, Liu Q. Keratin gene expression signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma. Oncology Letters. 2026;32(3):1-13. doi:10.3892/ol.2026.15774

BibTeX
@article{Chen2026,
  author = {Chen, Aohui and Gao, Ting and Liu, Fengqi and Zhao, Mingyue and Bai, Ruizhen and Liu, Quan},
  title = {Keratin gene expression signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma},
  journal = {Oncology Letters},
  year = {2026},
  volume = {32},
  number = {3},
  pages = {1--13},
  doi = {10.3892/ol.2026.15774}
}
Kostenlos starten →